Tag Archives: France

Orphan Drug Adoption: the More Regulation, the Better

New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks. In his study, ‘The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries,’ John Matthews, Associate Director of […]
Posted in Europe, Global, Market Access, Orphan Drugs, pricing, Regulatory | Also tagged , , , , , | Leave a comment

Too Much Sauce Hollandaise? Pharma, France, and Socialism

Will France’s new socialist president, François Hollande, prove too strong for pharma’s taste? Reflector, Pharm Exec’s EU correspondent, reports. So it has happened. A leading European country has gone against the predominant political grain, and elected a socialist head of state. France is now ruled by François Hollande, a mild-mannered but avowedly drug-industry-skeptical president. Is […]
Posted in Global, Guest Blog | Also tagged , , , , | Leave a comment

Taxing Times for French Pharma

By Nathan Jessop. While French politics has taken a decisive shift to the left with the election of the country’s first socialist president for 17 years, it does not look like Francois Hollande will be changing or derailing any of the existing — and sometimes quite radical — healthcare reforms that the outgoing Nicolas Sarkozy had […]
Posted in Global, Guest Blog | Also tagged , , , , , | Leave a comment

2012: A Good, Bad, and Ugly Year for France's Servier

By Nathan Jessop. Whichever way you look at it, 2012 will be a dramatic year for Servier. The French company has a number of collaborations that could lead to a new generation of products, but any positive news from these developments is likely to be overshadowed by the ongoing safety scandal of its diabetes treatment […]
Posted in Europe, Global, Guest Blog, Regulatory, Safety | Also tagged , | Leave a comment
  • Categories

  • Meta